PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Dose-Specific Network Meta-Analysis Reaffirms Antipsychotics for Acute Mania

risperidoneolanzapinehaloperidollithiumvalproatequetiapineasenapinearipiprazolecariprazinepaliperidoneziprasidonetamoxifencelecoxiballopurinolantipsychoticsmood stabilizersbipolar disorderacute manianetwork meta-analysisdose-responsepediatric psychiatry Psychiatry / Psychopharmacology

Background Information

Risperidone tops the list for acute bipolar mania efficacy.

Acute bipolar mania significantly impacts individuals' social and economic well-being, making effective management crucial. The network meta-analysis shows risperidone 3 mg/day was most effective, while several other drugs also significantly outperformed placebo in symptom improvement. The findings align with existing guidelines, highlighting the need for careful consideration of drug efficacy versus lower-quality evidence indicated by larger effect sizes. Risperidone and several other medications are effective for acute bipolar mania, but quality of studies should guide usage.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Fornaro M, Di Lorenzo C, Kishi T, Daray FM

Citation: Fornaro M, Di Lorenzo C, Kishi T, et al. Efficacy, acceptability, and related outcomes of pharmacological interventions for acute bipolar mania: a systematic review and dose-related network meta-analysis across different age groups. Journal of affective disorders. 2026;414:122329. doi:10.1016/j.jad.2026.122329

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.